Despite Europe now being over a year on from implementation of the General Data Protection Regulation (GDPR), it remains a tough pill to swallow. Not only because the GDPR is a volatile formula hard to stabilize at the best of times, but also because of its, as yet, untested implications for R&D.
It is hard to undersell the importance of R&D and yet excruciatingly simple to justify. It is the future of pharma and without it, there will be no new drugs, no new treatments, and no new devices - it is innovation. If the United Kingdom is to be the "world’s most innovative economy" and ensure the UK Life Sciences Strategy is a successful roadmap to the country being at the forefront of R&D, we will need to get the details right.
Getting the details right is not just about taking samples, patient data, and collating basic research. It is also about wider collaboration and pursuing innovation through the UK’s network of world-renowned research facilities, educational institutions, and leading industry champions. But where does one start when implementing GDPR in R&D? Why with the patient, of course, and a little thing called ‘consent’.
Read the full article in Pharmaceutical Technology Group.
For further information please contact Laura Barrell in our Pharmaceuticals Law and Life Sciences team on 01923 919 313, or complete the form below.